Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia

Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the rationale for the expansion cohort of the phase 2 CLOVER-WaM trial evaluating CLR 131 in these patients, and other anticipated research trends in this paradigm.

Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert.

OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Radhakrishnan Ramchandren, MD, professor and chief of the Division of Hematology/Oncology at the University of Tennessee Medical Center, to discuss the development of the novel small molecule radiotherapeutic phospholipid ether/phospholipid drug conjugate (PDC) CLR 131 in Waldenström macroglobulinemia.

CLR 131 is a novel small-molecule radiotherapeutic PDC that is designed to deliver cytotoxic radiation to cancer cells and stem cells.

The agent is under investigation in the phase 2 CLOVER-1 study (NCT02952508) in which investigators are evaluating its safety and efficacy in patients with select B-cell malignancies including multiple myeloma, indolent chronic lymphocytic leukemia, small lymphocytic leukemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, central nervous system lymphoma, and Waldenström macroglobulinemia who have been previously treated with standard therapy.

Results from the study showed significant responses in the cohort of patients with Waldenström macroglobulinemia, leading Cellectar Biosciences, the developer of the agent, to meet with the FDA and launch a single-arm expansion cohort of CLOVER-1 in this patient population.

CLOVER-WaM is a pivotal expansion cohort that will evaluate the efficacy of CLR 131 in adult patients with Waldenström macroglobulinemia who have received at least 2 prior lines of therapy, including those who have had a suboptimal response or failed treatment with a BTK inhibitor.

In our exclusive interview, Ramchandren discussed current unmet needs in Waldenström macroglobulinemia and ongoing research with the phospholipid ether/phospholipid drug conjugate CLR 131 in this population.

Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLiveOn Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLiveOn Air®.

*OncLiveOn Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.